Background: Pulmonary artery sarcoma (PAS) is a rare malignant neoplasm with an aggressive behavior and often difficult to distinguish from pulmonary thromboembolic disease. Aim: To assess the demographic, clinical, and radiological characteristics of PAS and clinical course. Design and Methods: We retrospectively identified and analyzed all patients with PAS seen at Mayo Clinic in Rochester, Minnesota, between January 1, 1996 and July 31, 2015. Results: Of nine patients (5 women and 4 men; median age 55 years [range, 24-74 years]), eight were diagnosed while alive with surgical (n ¼ 6) or catheter-based endovascular biopsy (n ¼ 2); the remaining patient was diagnosed at postmortem examination. All tumors manifested on CT as filling defect in the main, right or left pulmonary artery and were not associated with peripheral filling defects in seven patients. Seven patients were initially treated with anticoagulant therapy for presumed PE; two patients were suspected to have tumor based on constrictive or expanding effect seen on CT. Five patients died after a mean duration of 2.1 years (10 months-4.25 years) after diagnosis. Two patients are alive with recurrence and metastases of the disease 23 and 27 months after diagnosis, respectively; one remaining patient is alive and disease-free 116 months after diagnosis. Conclusions: Although PAS is associated with a poor prognosis, long-term survival is possible and can be improved by early diagnosis and prompt surgical resection. Atypical appearance on CT including central mass-like lesion without peripheral emboli and constrictive or expanding effect should raise suspicion of PAS.
Introduction
Pulmonary artery sarcoma (PAS) is a rare disease associated with a high mortality rate. 1 Clinical and radiological presentation can be difficult to distinguish from pulmonary embolism (PE), 2 often resulting in a delay in diagnosis and treatment.
Advanced radiologic imaging techniques may allow early recognition of PAS when the diagnosis is suspected and facilitate prompt surgical resection and chemo-radiation therapy, when needed, to offer the best opportunity of prolonged survival and possible cure.
The objective of the study was to analyze demographic, clinical and radiological features associated with PAS as well as management and clinical course to gain additional insights into earlier diagnosis and optimal management for PAS.
Materials and methods

Study subjects
Using a computer-assisted search of medical records (using the term 'pulmonary artery' cross-indexed with 'vascular neoplasm' or 'sarcoma'), we identified nine patients who were diagnosed with PAS with histologic confirmation at the Mayo Clinic in Rochester, Minnesota, between January 1, 1996 and July 31, 2015 (19.6 years). The current study was approved by the Mayo Clinic Institutional Review Board.
Clinical data
Medical records, imaging studies and histologic specimens were reviewed in detail, and data related to the following aspects were retrieved: age, gender, clinical presentation, radiological findings, histopathological features, diagnosis, treatment and follow-up.
Statistical analyses
Continuous variables are presented as median and range (minimum, maximum), when appropriate, whereas categorical variables are presented as frequency and percentage.
Results
A total of nine patients with PAS were identified; five were female ( Table 1 ). The median age at diagnosis was 55 years (range, 24-74 years). The presenting symptoms included dyspnea (100%), cough (22%), syncope/presyncope (22%) and hemoptysis (11%). All patients underwent radiologic evaluation that included chest computed tomography (CT) with intravenous contrast; other imaging studies included magnetic resonance imaging (n ¼ 2), positron emission tomography (n ¼ 2).
Based on initial chest CT findings, seven (78%) were diagnosed to have thromboembolic PE and begun on anticoagulant therapy. In remaining two cases, malignancy was suspected on initial evaluation because of the appearance on CT of a constricting mass narrowing the right main pulmonary artery and a mass-like filling defect expanding the right pulmonary artery lumen with extension into the hilar region, respectively. The latter patient underwent additional imaging studies including a chest MRI and 18 F-FDG PET/CT both of which suggested a pulmonary vascular neoplasm including mild to moderate increased FDG uptake in the intravascular mass. In all nine patients, the filling defect was located in the main, right or left pulmonary artery ( Figure 1 ) and was not associated with peripheral filling defects in seven patients; in the two remaining patients, filling defects in segmental arteries were identified.
Among seven patients initially treated for PE, further investigations were performed for persistence or worsening of symptoms despite anticoagulant therapy and lack of improvement in the vascular filling defect. One of these patients underwent both chest MRI and 18 F-FDG PET/CT to differentiate possible PE from vascular tumor but the results of both studies were inconclusive and the patient continued to be managed with anticoagulation before eventual diagnosis of PAS at surgical resection 7 months after the initial PE diagnosis. Median of delay between the initial diagnosis of PE and eventual diagnosis of PAS among these seven patients was 2.4 months (10 days-15.2 months).
Pulmonary angiography was performed in five patients; four studies demonstrated elevated pulmonary artery pressures and was normal in the remaining patient. Median value for mean pulmonary arterial pressure was 30 mmHg (range 11-38). Two of these patients underwent an endovascular biopsy during the procedure which demonstrated PAS.
One patient died before definite diagnosis of PAS which occurred at the time of the postmortem examination ( Figure 2) ; eight patients underwent surgical resection of PAS (Table 2 and 3). One patient (patient 5) did not receive adjuvant therapy; two patients (patients 1 and 2) received postoperative radiotherapy; three patients (patients 3, 4 and 7) had adjuvant chemotherapy, which included doxorubicin, ifosfamide, and dacarbazine for patient no. 3, gemcitabine and paclitaxel for patient no. 4, and adriamycin for patient no.7; and 2 patients (patients 6 and 8) had combined radiotherapy and chemotherapy which included doxorubicin and ifosfamide. Five patients (patients 1, 2, 3, 6 and 7) died at 34, 19, 10, 51 and 12 months after surgical resection, respectively. All five died with recurrence and metastasis of tumor despite adjuvant therapy. Two patients (patients 4 and 8) are alive at 27 and 23 months, both with recurrence of disease despite adjuvant chemotherapy. One patient (patient 5) is alive at 116 months after surgical resection, without clinical or radiologic signs of tumor recurrence or metastasis (Table 2) . Median survival was 23.6 months. (range 10 days to 116.6 months)
The histopathologic subclassification ( 
Discussion
Pulmonary artery intimal sarcoma (PAS) is very rare with an incidence of 0.001-0.03% among autopsy cases. 3 It was first described in 1923 by Mandelstamm 4 and since then only a few hundred cases have been reported. 5, 6 The majority of cases are diagnosed in middle-aged patients although broad age range has been reported (13-86 years) with a slight female predominance, similar to our findings. 7 Patients usually present with nonspecific symptoms, including dyspnea, chest pain, cough and hemoptysis. Clinical presentation resembles that of pulmonary thromboembolism as evidenced in our study; seven of nine patients (78%) were initially diagnosed to have pulmonary thromboembolism and were treated with anticoagulation therapy.
The prognosis for patients with PAS is poor, in part, due to its central location. PAS usually arises within the main or proximal pulmonary arteries or the pulmonary valve area and commonly invades contiguous structures such as the right ventricular outflow tract. 8, 9 In addition, most patients experience recurrence and metastatic disease after surgical resection. The most common site for metastasis is the lung parenchyma. 9, 10 In our study, two patients eventually died from recurrence and metastases identified within the thorax. Review of the literaturesuggests PAS to be more commonly associated with brain metastases compared to other soft tissue sarcomas. 11 Since our patients did not all undergo brain imaging or full autopsy it is possible that brain metastases went undiagnosed. The median survival without surgery has been reported to be 1.5 months after diagnosis while surgical intervention was associated with a median survival time of 10 months. 12 One of our patients is alive almost 10 years after surgical resection of PAS and without evidence of recurrence or metastasis. Surgical resection remains the mainstay of treatment for PAS since complete resection offers the best chance for a potential cure as seen in one of our patients (patient no. 5). Early diagnosis plays crucial role in achieving curative surgical resection. The role of nonsurgical treatment is still controversial. 13 F-FDG PET/CT can be considered for differentiation between tumor and thromboembolic disease in the setting of suspicious CT features. In the past, PAS was considered a single disease entity based on the anatomic origin, 5 and histopathological classification has not been considered to be of clinical or prognostic significance. Our surviving patient at 116 months had a high-grade spindle cell sarcoma despite its association with poor prognosis based on prior reports. Huo et al. 5 (68 months) and Burke 20 (120 months) reported their longest surviving patients to have leiomyosarcoma. A comprehensive clinicopathologic evaluation of additional PAS cases is needed to clarify the association between histologic subtypes and prognosis. In summary, PAS is extremely rare tumor that is commonly confused for PE on initial presentation but may be suspected based on atypical features on CT (Table 4) . Early diagnosis and complete surgical resection offer best chance for prolonged survival. Advanced imaging with MRI and PET may help differentiate PAS from PE. The role of adjuvant therapy remains controversial in improving survival.
Conflict of interest: None declared. 
